Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — hap­pi­ly — run­ning a lit­tle biotech

4 months ago
People
Bioregnum

Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics deal stands out

4 months ago
Deals
R&D

Arie Bellde­grun and David Chang god­fa­ther the $110M launch of a new cell ther­a­py play­er. And this one is al­so think­ing big

4 months ago
Startups
R&D

Scoop: Gilead’s CAR-T play­er Kite waves good­bye to re­search chief Pe­ter Em­tage as an­oth­er top ex­ec hits the ex­it

4 months ago
People
Cell/Gene Tx

Brent Saun­ders piv­ots from Al­ler­gan sale to a $460M SPAC, mak­ing him an overnight play­er in one of the hottest mon­ey-rais­ing gam­bits in biotech

4 months ago
Deals

Long­time biotech vet An­drew Hirsch is tak­ing the top job at C4 — and he clear­ly has some big plans

4 months ago
People
R&D

Game change: A fron­trun­ner in the cell ther­a­py 2.0 field of­fers a first look at their lead ther­a­py. And it’s a doozy

4 months ago
Cell/Gene Tx

A pair of Bay Area biotech up­starts with deep pock­ets and a shared in­ter­est in cu­ra­tive can­cer drugs join R&D forces

4 months ago
Startups
R&D

GSK, Vir bar­rel in­to a fast PhII/III for their lead Covid-19 an­ti­body, chas­ing a mov­ing tar­get with quick OK in sight

4 months ago
R&D
Coronavirus

Dri­ving to the $278M mark on rais­es, a leg­endary R&D ex­pert sets his sights on an­oth­er piv­otal goal line

4 months ago
People
Financing

Bris­tol My­ers bets $475M cash on a block­buster shot at break­ing the mold in im­muno-on­col­o­gy — with a po­ten­tial IL-12 game-chang­er

5 months ago
Deals

Bio­Marin CSO diss­es ri­vals for the he­mo­phil­ia A gene ther­a­py crown: Way be­hind, fac­ing big re­cruit­ment chal­lenges and at best a .6 on the gen-one scale

5 months ago
Bioregnum
Cell/Gene Tx

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo study

5 months ago
Bioregnum
R&D

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed every­thing

5 months ago
People
Coronavirus

A wob­bly Bio­gen makes a sur­prise switch in the ex­ec­u­tive suite, trig­ger­ing a re­newed burst of M&A chat­ter

6 months ago
People

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

6 months ago
Deals

Eli Lil­ly’s mirik­izum­ab joins the club beat­ing up on Cosen­tyx as an­oth­er head-to-head study leaves No­var­tis’ drug in the dust

6 months ago
R&D

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

6 months ago
Startups
Bioregnum

A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price?

6 months ago
Bioregnum

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

6 months ago
Bioregnum
Coronavirus

Win or lose on the mar­ket­ing OK, the FDA just gunned down GSK’s bright hopes for their BC­MA ther­a­py

6 months ago
Bioregnum
Regulatory

The home run count: The $100M+ mega-round boom in biotech in­spired a $7.3B feed­ing fren­zy — so far this year

6 months ago
Bioregnum
R&D

A new study points to $6.5B in pub­lic sup­port build­ing the sci­en­tif­ic foun­da­tion of Gilead­'s remde­sivir. Should that be re­flect­ed in the price?

6 months ago
Bioregnum
R&D

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

6 months ago
Bioregnum
Pharma
First page Previous page 12345 Next page Last page